Dutch Amarna Therapeutics enters research collaboration with Spanish FPS, examining the efficacy of its SV40-based SVec™ gene delivery vector platform technology in diabetes mellitus type 1 and multiple sclerosis |
| September 25, 2020 | September 2020 Bond Updates |
|
LEIDEN, The Netherlands and SEVILLE, Spain, Sept. 25, 2020 /PRNewswire/ -- Amarna Therapeutics, a Dutch privately held biotechnology company developing the next-generation SV40-based gene delivery vector platform transforming gene-replacement and immunotherapy across many disease areas.... |
| View more at: https://www.prnewswire.com:443/news-releases/dutch-amarna-therapeutics-enters-research-collaboration-with-spanish-fps-examining-the-efficacy-of-its-sv40-based-svec-gene-delivery-vector-platform-technology-in-diabetes-mellitus-type-1-and-multiple-sclerosis |
| Related News |
|